The 2026 proposal is seemingly shifting the TRT landscape, moving it further from the “use with caution” territory.
High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
The FDA’s May 2026 guidance on cell and gene therapies provides for CMC flexibilities while insisting on quality and ...
The US Food and Drug Administration (FDA) on Friday issued draft guidance to assist sponsors in providing necessary ...
The FDA panel will review seven peptides and decide if they should be added to a list of substances that can be safely ...
The US Food and Drug Administration (FDA) has updated 17 draft product-specific guidances (PSGs) to assist sponsors in submitting abbreviated new drug applications (ANDAs) for injectable peptide ...
A new guidance document issued by the FDA this week offers recommendations for how makers of prescription biosimilars and biologic reference products should approach promotional advertising and ...
The joint guidelines state that AI should be explainable and interpretable. Drug developers can no longer submit an ...
Evolving FDA regulations pose real risks for unwary food brands, but those who proactively invest in compliance can transform these challenges into opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results